Cabazitaxel
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1355 publications
Optimizing the Systemic Treatment for Metastatic Castration-Resistant Prostate Cancer in Lower-Middle-Income Countries: A 7-Year Analysis of the Brazilian Public Health System.
Journal: JCO global oncology
Published: March 31, 2026
Excellent Response to Combined 223Ra-dichloride and Enzalutamide After Failure of 177Lu-PSMA Radioligand Therapy.
Journal: Clinical nuclear medicine
Published: January 24, 2026
Chemotherapy-Forward Management of Advanced Prostate Cancer: Taxane Timing, Sequencing and the Real-World Place of Immunotherapy.
Journal: Cancers
Published: January 17, 2026
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.
Journal: JAMA network open
Published: January 16, 2026
Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical genitourinary cancer
Published: December 25, 2025
Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 16, 2025
Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: December 15, 2025
Prognostic value of the modified Glasgow Prognostic Score and Prognostic Nutritional Index in prostate cancer treated with cabazitaxel.
Journal: International journal of clinical oncology
Published: December 12, 2025
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 11, 2025
Case Report: Deep and durable PSA response to same-agent enzalutamide rechallenge in metastatic castration-resistant prostate cancer without chemotherapy.
Journal: Frontiers in oncology
Published: December 03, 2025
Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 01, 2025
Last Updated: 04/28/2026